Haisco Pharmaceutical Group Co Ltd: Riding the Wave of Innovation in Pharmaceuticals
In the dynamic landscape of the pharmaceutical sector, Haisco Pharmaceutical Group Co Ltd, a prominent player based in Shannan, China, continues to make significant strides. Listed on the Shenzhen Stock Exchange, Haisco specializes in developing, manufacturing, and selling a range of drug formulations and active pharmaceutical ingredients, focusing on hepatobiliary disease medications, anti-infective drugs, and nutrition drugs.
As of June 10, 2025, Haisco’s stock closed at 43.36 CNH, with a market capitalization of 49.19 billion CNH. Despite a high price-to-earnings ratio of 141.83, the company’s recent activities and market trends suggest a promising outlook.
Market Movements and Sector Performance
The broader market saw a mixed performance on June 12, 2025, with the Shenzhen Composite Index rising by 0.26% to 2067.15 points, while the Shanghai Composite Index edged up by 0.01% to 3402.66 points. The Shenzhen Stock Exchange witnessed over 2300 stocks climbing, with more than 70 hitting their daily price limits. Notably, the innovative drug concept stocks, including Haisco’s peer, Haisi Pharmaceutical (002653), experienced a surge, with Haisi’s stock reaching its daily price limit.
Innovative Drug Developments
Haisi Pharmaceutical, a key player in the innovative drug sector, has been at the forefront of recent market excitement. On June 9, 2025, Haisi announced that its innovative drug HSK47977, a novel oral small molecule anti-tumor drug, received approval for clinical trial applications from the National Medical Products Administration. This development marks a significant milestone for Haisi, as HSK47977 is intended for the treatment of lymphoma and holds independent intellectual property rights.
The approval of HSK47977’s clinical trial application has not only bolstered Haisi’s market position but also contributed to the broader innovative drug concept’s momentum. This sector has seen sustained activity, with stocks like Haisi and Oseco (002688) reaching their daily price limits, while others like Shu Tai Shen and Rui Zhi Pharmaceutical also experienced substantial gains.
Financial Highlights and Strategic Moves
In addition to its innovative drug developments, Haisi has been active in financial maneuvers. On June 9, 2025, the company reported a significant financing buy-in of 1.007 million yuan, accounting for 10.83% of the day’s total buy-in amount. This move, coupled with the release of a portion of its pledged shares by its controlling shareholder, indicates a strategic effort to strengthen its financial position and support ongoing and future projects.
Looking Ahead
As Haisi continues to capitalize on its innovative drug pipeline and strategic financial decisions, the company is well-positioned to leverage the growing demand for advanced pharmaceutical solutions. The recent approval of HSK47977’s clinical trial application is a testament to Haisi’s commitment to innovation and its potential to make significant contributions to the healthcare sector.
For investors and industry observers, Haisi Pharmaceutical’s trajectory offers a compelling narrative of growth and innovation in the pharmaceutical industry. With a focus on cutting-edge drug development and strategic financial management, Haisi is poised to continue its upward trajectory in the competitive landscape of healthcare and pharmaceuticals.